Rain Enhancement Technologies Holdco, Inc. (RAIN)
| Market Cap | 19.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.41M |
| Shares Out | 7.53M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,736 |
| Open | 3.136 |
| Previous Close | 2.660 |
| Day's Range | 2.630 - 3.136 |
| 52-Week Range | 2.590 - 10.840 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RAIN
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology. The company is based in Naples, Florida. Rain Enhancement Technologies Holdco, Inc. operates as a subsidiary of Rainwater, LLC. [Read more]
Financial Performance
Financial StatementsNews
Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer
NAPLES, Fla.--(BUSINESS WIRE)--Rain Enhancement Technologies Holdco, Inc. (“RET Holdco” or the “Company”) (Nasdaq: RAIN, RAINW), an emerging company developing rainfall generation technology, today an...
Pathos AI Completes Acquisition of Rain Oncology
CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acq...
RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology In...
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will ...
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on th...
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Bios...
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (NASDAQ:RAIN) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP,...
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations ...
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rain Oncology Inc...
The Law Offices of Frank R. Cruz Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) on behalf of investors concerning the Company's...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "th...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc....
RAIN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Rain Oncology Inc.
NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) violated federal securities laws. CURRENT INV...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc....
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial –
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $RAIN #RAIN--The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm.
Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care –
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
Rain Oncology, Inc. (NASDAQ:RAIN) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Br...
Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 bask...
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.
Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress
NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milad...
Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript
Rain Oncology Inc. (NASDAQ:RAIN) Q4 2022 Results Conference Call March 9, 2023 5:00 PM ET Company Participants Dan Ferry - LifeSci Advisors Avanish Vellanki - Chief Executive Officer Robert Doebele -...
Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 baske...